Pharma ADMET Testing Market Report 2026

The pharma admet testing market size has grown rapidly in recent years. It will grow from $10.7 billion in 2025 to $11.99 billion in 2026 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to increasing pharmaceutical r&d investments, expansion of preclinical drug testing requirements, rising complexity of drug molecules, growing regulatory emphasis on safety profiling, availability of advanced laboratory technologies.

The pharma admet testing market size is expected to see rapid growth in the next few years. It will grow to $19.27 billion in 2030 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to increasing demand for cost-efficient drug development, rising adoption of predictive admet analytics, expansion of personalized medicine pipelines, growing integration of machine learning in drug testing, increasing outsourcing of admet testing services. Major trends in the forecast period include increasing adoption of in silico admet modeling tools, growing use of high-throughput screening technologies, expansion of AI-based toxicity prediction platforms, rising integration of omics data in drug testing, enhanced focus on early-stage drug safety evaluation.

The increase in the number of clinical trials is expected to drive the growth of the pharma ADMET testing market in the coming years. A clinical trial is a research study involving human participants that evaluates the safety, effectiveness, and potential side effects of medical interventions such as new drugs, medical devices, diagnostic methods, or treatment protocols. The rise in clinical trial activity significantly increases the need for comprehensive evaluations of drug safety and efficacy, thereby strengthening demand for pharma ADMET testing. This growth highlights the importance of customized assessments across a wide range of drug candidates and patient populations. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry, a UK-based nonprofit organization, the number of industry-initiated clinical trials in the UK increased from 411 in 2022 to 426 in 2023, representing a growth of 3.7%. Therefore, the rising number of clinical trials is contributing to the expansion of the pharma ADMET testing market.

Major companies operating in the pharma ADMET testing market are focusing on the introduction of advanced solutions such as artificial intelligence-driven drug design to enhance prediction accuracy and accelerate drug development processes. Artificial intelligence-driven drug design involves the use of AI technologies to create and optimize drug molecules without relying solely on traditional laboratory-based screening or manual medicinal chemistry approaches. For example, in June 2025, Simulations Plus Inc., a US-based provider of cheminformatics software for the pharmaceutical industry, launched ADMET Predictor 13, an advanced AI-driven drug design and ADMET prediction platform. This platform integrates improved high-throughput physiologically based pharmacokinetic (PBPK) simulations with a generative AI-enabled drug design engine, enabling more efficient workflows and supporting faster, data-driven decision-making throughout drug development.

In November 2024, Concept Life Sciences Limited, a UK-based integrated drug discovery and development company specializing in medicinal chemistry, acquired Charnwood Discovery Ltd for an undisclosed amount. Through this acquisition, Concept Life Sciences aims to strengthen its end-to-end drug discovery and development capabilities by incorporating Charnwood Discovery’s expertise in medicinal chemistry and ADME and ADMET testing services. This strategic move is intended to streamline early-stage drug development and expand the company’s ability to deliver comprehensive solutions to pharmaceutical and biotechnology clients. Charnwood Discovery Ltd is a UK-based contract research organization focused on medicinal ADMET testing services.

Major companies operating in the pharma admet testing market are Thermo Fisher Scientific Inc., The Merck Group, Laboratory Corporation of America Holdings, IQVIA Inc., PPD ICON plc, Agilent Technologies Inc., Wuxi AppTec Co. Ltd., Catalent Inc., Covance Inc., Charles River Laboratories International Inc., Eurofins Scientific SE, Beckman Coulter Inc., Perkinelmer Inc., Albany Molecular Research Inc., Evotec A.G., CMIC Holdings Co. Ltd., Promega Corporation, Aptuit LLC, Symeres B.V., Biovia Corp., BioIVT LLC, Cyprotex Limited, InSphero AG, Admescope Ltd., Accelrys Inc.

Asia-Pacific was the largest region in the pharma ADMET testing market in 2025. The regions covered in the pharma admet testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharma admet testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the pharma ADMET testing market by increasing costs of imported laboratory instruments, reagents, imaging systems, and high-performance computing hardware used in in vitro, in vivo, and in silico testing. Pharmaceutical companies and CROs in North America and Europe are most affected due to reliance on imported analytical equipment, while Asia-Pacific faces higher costs for advanced testing infrastructure. These tariffs are increasing operational expenses and slowing laboratory upgrades. However, they are also encouraging domestic manufacturing of lab equipment, regional reagent production, and localized development of ADMET testing platforms.

The pharma admet testing market research report is one of a series of new reports that provides pharma admet testing market statistics, including pharma admet testing industry global market size, regional shares, competitors with a pharma admet testing market share, detailed pharma admet testing market segments, market trends and opportunities, and any further data you may need to thrive in the pharma admet testing industry. This pharma admet testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pharma ADMET testing involves a range of procedures and assays used in the pharmaceutical industry to evaluate the absorption, distribution, metabolism, excretion, and toxicity of drug candidates. This testing is essential for assessing the safety and effectiveness of potential drugs before they advance to clinical approval.

The primary types of pharma ADMET testing include in vivo ADMET testing, in vitro ADMET testing, and in silico ADMET testing. In vivo ADMET testing assesses a drug’s absorption, distribution, metabolism, excretion, and toxicity within a living organism. Pharma ADMET testing is widely applied in drug discovery and development to identify drug candidates with favorable pharmacokinetic characteristics. The technologies employed include cell culture techniques, high-throughput screening, molecular imaging, and OMICS technologies, which are used to evaluate systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and other toxicity endpoints.

The pharma ADMET testing market consists of revenues earned by entities by providing services such as in vitro screening, in vitro metabolism, and metabolite testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharma ADMET testing market also includes the sales of membranes, buffer systems, and analytes that are used in the assays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.